A world-first melanoma vaccine which personalises treatments for patients may put an end to melanoma as a "death sentence", according to Australian experts.
Results of an early trial by Biotech company Moderna indicate the personalised treatment reduces the risk of recurrence or death from melanoma by 44 per cent, compared with results from its immunotherapy drug alone.
